标题
Patient-Centered Diabetes Care of Cancer Patients
作者
关键词
-
出版物
Current Diabetes Reports
Volume 21, Issue 12, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-12-13
DOI
10.1007/s11892-021-01435-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
- (2021) V. Lo Preiato et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism
- (2021) Diane Mourad et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan
- (2021) Kaori Hisanaga et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
- (2021) Imke Grimmelmann et al. EUROPEAN JOURNAL OF CANCER
- Endocrine toxicities of immune checkpoint inhibitors
- (2021) Jordan J. Wright et al. Nature Reviews Endocrinology
- Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study
- (2021) Marie Bastin et al. THERAPIE
- Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
- (2021) Amy L. Zhang et al. Frontiers in Endocrinology
- A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital
- (2021) Felix Aberer et al. Journal of Clinical Medicine
- Hypophysitis from immune checkpoint inhibitors: challenges in diagnosis and management
- (2021) Anupam Kotwal Current Opinion in Endocrinology Diabetes and Obesity
- Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes
- (2020) Z. Quandt et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Diabetes Technology in the Inpatient Setting for Management of Hyperglycemia
- (2020) Georgia M. Davis et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Acquired lipodystrophy associated with immune checkpoint inhibitors
- (2020) Subashini S. Gnanendran et al. MELANOMA RESEARCH
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
- (2020) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
- (2020) Zoe Quandt et al. Annual Review of Medicine
- Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
- (2020) Nicola Silvestris et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
- (2020) Misty Shields et al. Oncotarget
- 12. Older Adults: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer
- (2020) Bairavi Shankar et al. JAMA Oncology
- Challenges in the management of people with diabetes and cancer
- (2019) T. A. Chowdhury et al. DIABETIC MEDICINE
- T-Lymphocyte Infiltration to Islets in the Pancreas of a Patient Who Developed Type 1 Diabetes After Administration of Immune Checkpoint Inhibitors
- (2019) Sho Yoneda et al. DIABETES CARE
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab
- (2019) Beckey Trinh et al. DIABETES CARE
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes
- (2019) Venessa H M Tsang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2019) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
- (2019) Anupam Kotwal et al. THYROID
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
- (2018) Romualdo Barroso-Sousa et al. CANCER
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis
- (2018) Jetty A. Overbeek et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment
- (2018) Jonathan Pearson-Stuttard et al. Lancet Diabetes & Endocrinology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
- (2018) Marcus D. Goncalves et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring
- (2017) Yusuke Yata et al. INTERNAL MEDICINE
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome
- (2016) Elizabeth Hansen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies
- (2016) Jennifer W. Wu et al. DIABETES CARE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
- (2016) Jonathan W. Goldman et al. ONCOLOGIST
- Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
- (2016) Khurum H. Khan et al. ONCOLOGIST
- A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients
- (2016) Yusook Jeong et al. Cancer Research and Treatment
- Diabetes and mortality in patients with prostate cancer: a meta-analysis
- (2016) Junga Lee et al. SpringerPlus
- Low programmed cell death-1 (PD-1) expression in peripheral CD4+T cells in Japanese patients with autoimmune type 1 diabetes
- (2015) R. Fujisawa et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus
- (2015) Valentina Perri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
- (2014) Rahul Aggarwal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hyperglycemia, a Neglected Factor during Cancer Progression
- (2014) Wanxing Duan et al. Biomed Research International
- Glucocorticoid-induced hyperglycemia (糖皮质激素诱导的高血糖)
- (2013) Antonio Perez et al. Journal of Diabetes
- The Links Between Insulin Resistance, Diabetes, and Cancer
- (2012) Etan Orgel et al. Current Diabetes Reports
- Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms
- (2012) Biagio Arcidiacono et al. Experimental Diabetes Research
- Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
- (2012) Naifa L. Busaidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Low CTLA-4 expression in CD4+ helper T-cells in patients with fulminant type 1 diabetes
- (2011) Fumitaka Haseda et al. IMMUNOLOGY LETTERS
- Diabetes and Cancer: A Consensus Report
- (2010) E. Giovannucci et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Insulin-Mediated Acceleration of Breast Cancer Development and Progression in a Nonobese Model of Type 2 Diabetes
- (2010) R. Novosyadlyy et al. CANCER RESEARCH
- Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase
- (2010) L Zeng et al. ENDOCRINE-RELATED CANCER
- Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden
- (2009) J. M. Jonasson et al. DIABETOLOGIA
- Glucocorticoid-Induced Hyperglycemia
- (2009) John Clore et al. Endocrine Practice
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started